Revance Therapeutics, Inc. today announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units ("RSUs") to 31 employees. The RSUs vest over four years, with 25% of the underlying shares vesting on each of the four.
Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]
Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]
Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average […]
Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The […]